Abstract:Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung carcinoma (SCLC). LCNEC is considered aggressive, and the optimal treatment strategy and chemotherapy regimen remain undefined. We retrospectively evaluated a LCNEC patient cohort established from 1997 to 2015 at Mayo Clinic (Minnesota). A diagnosis of LCNEC was made when all WHO classification criteria were present in the tumor section examined. Clinical characteristics, treatment and outcomes were analyzed. Available radiology assessment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The study included 55 LCNEC patients. Median age at diagnosis was 63 years (range: 38-88); two thirds were men; and majority were smokers (94%). Clinical staging was I, II, III or IV in 52.8%, 9.1%, 14.5%, and 23.6% of cases, respectively. Forty-six percent of stage IV patients presented with brain metastases at time of diagnosis (n=6/13) and 18% (n=7/38) developed brain recurrence in the follow up period. Thirty-nine (71%) patients had surgery and 9 (16%) patients received adjuvant platinum-based chemotherapy. Sixty-five percent of patients with complete resection experienced disease recurrence with 80% recurring within 2 years of resection. Treatment data for first-line palliative chemotherapy were available on 23 patients: 10 received platinum/etoposide and 13 received other regimens. In 19 patients with available imaging; the overall response rate was 52.6% (95% CI, 31.7-72.7) and there was no difference in ORR between platinum/etoposide (ORR=55.6%) or platinum plus other agents (paclitaxel or pemetrexed; ORR=55.6%). The median survival time was 26.3 months (95%CI; 18.6-33.9); the 1-, 2-, 3- and 5-year overall survival rates (OS) were 75%, 53%, 36%, and 30%, respectively. Patients who received platinum/etoposide demonstrated longer median time to progression (TTP), and median OS than those who received ‘other’ regimens (14.7 months vs. 7.1 months; p value 0.07, and 28.2 months vs. 21.1 months; p value 0.22, respectively); the differences did not reach conventional statistical significance, likely due to the small sample size. Rigorous pathologic confirmation and genomic analysis are ongoing. LCNEC is associated with a poor prognosis and high recurrence rates after surgery. Advanced LCNEC patients are at high risk for brain metastases, therefore, routine brain imaging surveillance during follow-up may be beneficial. The chemotherapeutic responsiveness of LCNEC patients was intermediate between that of NSCLC and SCLC patients. Future prospective, multicenter, clinical trials are needed to determine the best chemotherapy regimen for these rare tumors.

Clinical Analysis Of 50 Eastern Asian Patients With Primary Pulmonary Large-Cell Neuroendocrine Carcinoma

Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?

Clinical Features And Outcomes Analysis Of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study

Lung Large Cell Neuroendocrine Carcinoma: an Analysis of Patients from the Surveillance, Epidemiology, and End-Results (SEER) Database

Clinicopathological Characteristics with EGFR, ALK, ROS1 Genetic Alternation and Prognostic Analysis of Primary Lymphoepithelioma-Like Carcinoma

Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma

44P A Large Population-Based Study on Large Cell Neuroendocrine Lung Cancer: A SEER Database Analysis

P3.15-015 LCNEC Tumor Location, Divided into Central and Peripheral Type, Has Distinct Clinicopathologic Feature, Genomic Characteristics and Survival

Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches

Clinicopathological Characteristics, Survival and Prognostic Factors in Gastrointestinal Large Cell Neuroendocrine Carcinoma

Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas

P1.07-036 Large Cell Neuroendocrine Carcinoma of the Lung: the Mayo Clinic Experience

Cfdna Analysis to Reveal Association of Genomic Features with Chemotherapy Response and Survival in Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma.

Population-based analysis of esophageal large cell neuroendocrine carcinoma between 2004 and 2015

Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.

Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study.

1114P Comparative Study of Combined Large Cell Neuroendocrine Carcinoma and Combined Small Cell Carcinoma in Resected High-Grade Neuroendocrine Tumors of the Lung

Combined Large Cell Neuroendocrine Carcinoma: Clinical Characteristics, Prognosis and Postoperative Management

Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma